← Return to Short acting Ocreotide

Discussion

Short acting Ocreotide

Neuroendocrine Tumors (NETs) | Last Active: Sep 2 3:29pm | Replies (9)

Comment receiving replies
@sophiarose

Thank you for your quick response
I took 3 infusions of Lanreotide in 2022 had to stop because side effects were severe I was switched to Ocreotide 2022-2023 for 9 infusions
The side effects weren’t as bad but it didn’t stop the cancer from taking on a life of its own so it was stopped
I was told that the way the long acting works is to give you doses of the drug at certain intervals during the 28 days
I was hoping that the short acting will just be daily level doses instead of heavy interval doses
However insurance I didn’t think of that
I have Medicare and pay for separate drug and medical coverage
I will have to check into that
Thank you so much
I wish you the best

Jump to this post


Replies to "Thank you for your quick response I took 3 infusions of Lanreotide in 2022 had to..."

Makes sense on why you want to try the short acting octreotide. I hope insurance covers it and it works well for you. If covered under the Medicare Part D plan, the good news is in 2025 there will be an out of pocket (copays) limit of $2000 for prescription meds. You are likely taking other meds that will be included in that limit. If home injection octreotide is not covered then unfortunately there wouldn’t be a limit. Blessings.